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ABSTRACT: Non-covalent encapsulation is an attractive ap-
proach for modifying the efficacy and physiochemical properties 
of both therapeutic and diagnostic species. Abiotic self-assembled 
constructs have shown promise, yet many hurdles between in vitro 
and (pre)clinical studies remain, not least the challenges associated 
with maintaining the macromolecular, hollow structure under non-
equilibrium conditions. Using a kinetically robust CoIII4L6 tetrahe-
dron we now show the feasibility of encapsulating the most widely 
used precursor in clinical nuclear diagnostic imaging, the gamma 
emitting [99mTc]TcO4− anion, under conditions compatible with in 
vivo administration. Subsequent SPECT imaging of the caged-an-
ion reveals a marked change in the biodistribution compared to the 
thyroid-accumulating free oxo-anion, thus moving clinical applica-
tions of (metallo)supramolecular species a step closer. 
Technetium-99m (t½ = 6 hours) is a gamma emitting radioactive 
isotope used in >80% of clinical nuclear diagnostic imaging scans, 
with over 40 million single-photon emission computed tomography 
(SPECT) scans annually carried out worldwide.1 The new genera-
tion of molecular imaging agents (including positron emission to-
mography (PET) tracers) target specific molecules associated with 
disease (e.g. enzymes, protein or other antigens), however, techne-
tium-based imaging agents have generally utilized lipophilicity, 
charge or other non-molecular actions, often to determine tissue 
blood flow as an indirect measure of function.2 Syntheses of mo-
lecular clinical imaging agents for SPECT involve reduction of the 
[99mTc]TcO4− anion, which is eluted directly from a 99Mo/99mTc 
generator. This can limit applications as the typical radiopharma-
ceutical kit must bring about in situ reduction of the +7 pertechne-
tate oxidation state, which can be difficult to control precisely and 
is often incompatible with chelator-biomolecule conjugates.3 The 
reliance on a reductive approach to technetium-based imaging 
agents is due to the assumption that the “chemical reactivity of the 
pertechnetate anion is negligible; it does not bind to any ligand”.1a  
While pertechnetate encapsulation has been investigated for nu-
clear waste stream management,4 similar chemistry has not been 
exploited for imaging agents. The speed and efficacy of non-cova-
lent encapsulation, avoiding additional reagents, brings advantages 
because of the rapid decay of the radioisotope, and the need to pro-
vide a simple clinical kit. Cationic coordination tetrahedra are 
known to bind small anions,5 thus encapsulation has the potential 
to break the paradigm that [99mTc]TcO4− cannot be used directly in 
targeted molecular SPECT imaging. The relative small size and 
monodispersity of a coordination cage (< 3 kDa, 1-2 nM) also pro-
vides advantages over larger nanoscale carriers; it should be possi-
ble to develop these compounds for effective distribution in the 
vasculature, and to give clearance via renal excretion on an imaging 
timescale, a common problem with nanoparticle systems.6 How-
ever, there are challenges with using self-assembled systems in vivo 
as most exist in an equilibrium state with their disassembled com-
ponents.7 This is less problematic for applications such as cataly-
sis,8 where intact species are typically favored. In contrast, in vivo 
conditions severely challenge equilibrium systems because of the 
low-concentration required for a safe dose and numerous compet-
ing “ligands”.9 This is particularly true for nuclear medicine appli-
cations, as the very high sensitivity and radioactivity means very 
small amounts (as low as nanograms) of the agent are usually ad-
ministered. 
Self-assembled coordination assemblies are known to possess 
interesting biological properties.10 It has also been shown that host-
guest chemistry can enhance in vitro cytotoxicity and improve cel-
lular uptake.11 However, in vivo investigations are extremely rare,12 
possibly due to concerns about structural integrity.  Recently, we 
started to explore an “assembly-followed-by-fixing” method for 
generating robust assemblies. This involves post-assembly oxida-
tion of dynamic CoII species to give non-equilibrium CoIII ana-
logues.13 Moving this system forward, the development of an in 
vivo imaging agent utilizing [99mTc]TcO4− encapsulation was an ap-
pealing option. The bio-distribution of the free [99mTc]TcO4− anion 
is well known,14 therefore any perturbation would validate the ap-
proach under pre-clinical conditions and by extension demonstrate 
the robustness of the system.  
Initially, our investigation focused on the host-guest chemistry 
of the tetrahedral [CoIII4L16]·12NO3 (C-1·12NO3, Figure 1a) in 
D2O using “cold” anions. As expected, more “hydrophobic” anions 
 bind best, with PF6− giving the highest Ka (91000 M−1; see Support-
ing Information) while the pertechnetate analogue, perrhenate 
(ReO4−) also showed significant affinity (61000 M−1). The binding 
of this anion is easy to observe due to slow exchange on the 1H 
NMR timescale, with separate signals for the empty and occupied 
capsule at sub-stoichiometric ratios (Figure 2). Anions including 
BF4−, ClO4− and even SO42− also bind, albeit more-weakly, with Ka 
ranging from 100 M−1 (SO42−) to 7000 M−1 (ClO4−). The relative 
affinities of these anions is difficult to accurately rationalize due to 
the interplay of multiple factors, including size and shape comple-
mentary, coulombic attraction and de-solvation energies.15 Consid-
ering other biological anions that might compete with a radio-
labelled cage, we also examined PO43−. This showed no evidence 
of binding in D2O, presumably because of the increasing de-solva-
tion penalty. The encapsulation of ClO4− has also been confirmed 
by X-ray crystallography (Figure 1b).   
 
Figure 1. (a) Chemical structure of anion-binding CoIII4L6 cages 
(only one ligand shown for clarity); X-ray crystal structures of (b) 
[ClO4⊂C-1]11+; (c) [ReO4⊂C-2]11+. Non-encapsulated anions and 
solvent molecules removed for clarity. Color Code: Co, orange; C, 
grey; N, light blue; O, red; Cl, green; Re, dark blue. 
 
Figure 2. 1H NMR spectra (500 MHz, D2O, 298 K) showing the 
encapsulation of ReO4− by C-112+. (a) C-1·12NO3 only; (b) C-
1·12NO3 + NH4ReO4 (free cage signals in red, occupied in pink). 
The assignments correspond to lettering shown in Figure 1a. 
Turning to [99mTc]TcO4− encapsulation, we started by investigat-
ing the concentration of C-112+ required to give quantitative (>95%) 
radiochemical yield (RCY) of radio-labelled species, as this would 
dictate the minimum dose in subsequent in vivo imaging experi-
ments. This was assessed using thin layer chromatography (TLC) 
on standard-phase silica gel; while free [99mTc]TcO4− elutes in wa-
ter with the solvent front, encapsulated [TcO4⊂C-1]11+ is retained 
on the baseline. Analysing the TLC plates using a gamma counter 
showed that full encapsulation could be achieved at 100 μM C-1, 
with an EC50 (cage concentration required for 50% RCY) of 14 μM 
(Figure 3, black squares). These preliminary experiments also 
showed that, as anticipated, cage labelling using encapsulation is 
facile and rapid, with the RCY invariant of mixing time from 5 
minutes to hours (data not shown).  
 
Figure 3. Radiochemical yield for [99mTc]TcO4− encapsulation as a 
function of cage concentration (C-1, black squares; C-2, red cir-
cles). For details see Supporting Information. 
Next, the RCY was assessed under a range of conditions de-
signed to probe the stability of the encapsulated species (Figure 4, 
grey bars). The RCY is maintained at a reasonable level (40-60%) 
after the addition of competing NO3−, Cl−and PO4(H)2−/3− anions 
that are relevant to in vivo use. In contrast, when anions which bind 
within C-1 (i.e. ClO4− and PF6−) were added to the radiolabelled 
cage, the stability was negligible. While neither ClO4− nor PF6− rep-
resent concerns from an in vivo perspective, they show that the high 
RCY is due to encapsulation rather than simple ion-pairing with the 
cage periphery. Further controls with assemblies possessing both 
smaller and larger cavities (i.e., analogous CoIII2L3 and CoIII4L6 
species12b, see Supporting Information) showed no discernible 
binding at 100 M, further demonstrating the complementary of C-
1 for the [99mTc]TcO4−  anion. The stability experiments with com-
petitive anions also show the RCY does not change as a function of 
time. In contrast, the same stability experiment carried out in serum 
showed a steady decrease in RCY, diminishing to negligible levels 
of intact host-guest system after 24 hours. As displacement by bio-
logical “guests” would likely be rapid, we attribute the slower re-
lease of the [99mTc]TcO4− anion to cage degradation, possibly facil-
itated by biological reductants (antioxidants). To test this, the reac-
tion of C-1 with excess glutathione was examined using 1H NMR 
spectroscopy (Figure S6).16 This showed the rapid disappearance 
of the diamagnetic signals of C-1, indicating a possible cage disas-
sembly mechanism that involves initial reduction of some or all of 
the CoIII centers.    
Considering structural modification to improve cage integrity in 
biological medium, we targeted stabilization of the +3 oxidation 
state. Reasoning that a stronger σ-donor ligand would achieve this, 
the novel 4-amino-2,2′-bipy analogue, C-2, was developed (Figure 
1a). It was also envisaged that the more strongly coordinating L2 
would also inhibit direct ligand substitution from either oxidation 
state. The diamino substituted ligand, L2, was synthesized in sev-
eral steps, starting with nitration of 2-bromopyridine-N-oxide, fol-
lowed by metal-catalyzed cross-coupling, then reduction and 
 homo-coupling reactions (see Supporting Information). The en-
hanced ligand “strength” became immediately apparent when pre-
paring C-2; equilibration of the CoII precursor required prolonged 
microwave irradiation. Even then, oxidation yielded a mixture of 
C-2 and the corresponding helicate [CoIII2L23]6+, which we attribute 
to probable kinetic trapping in the assembly phase of the reaction. 
Nonetheless, the smaller species could be removed using size-ex-
clusion chromatography, which gave a pure sample of C-2·12NO3 
in 26% yield. 
 
Figure 4. Stability of encapsulated complexes to different anions 
and conditions. 100 M solution of salt was added to each cage 
made at their respective EC95 (100 M for C-1 and 1.9 M for C-
2). For details see Supporting Information. 
Returning to radiochemical labelling experiments, we were de-
lighted to find that substitution of the cage structure with 12 amino 
groups had an unforeseen yet very positive impact on [99mTc]TcO4− 
encapsulation. In the absence of competing anions, the concentra-
tion of C-2 required to achieve >95% RCY was reduced to 1.9 μM, 
nearly 50-fold lower than C-1, with an EC50 value of just 0.05 μM 
(Figure 3, red circles). Furthermore, repeating the same anion dis-
placement experiments with C-2 showed that this increase in affin-
ity is specific to [99mTc]TcO4−, as higher stability is observed even 
with a much greater mole ratio of competing anions (Figure 4, red 
bars). Most significantly, however, we were gratified to see that the 
presence of serum gave no discernible drop in radiochemical sta-
bility over 24 hours, indicating that the amino groups have the de-
sired effect of increasing cage robustness. This improved stability 
also correlates with a lack of reactivity towards glutathione (Figure 
S7).   
 In light of the improved serum stability and lower dose required 
to fully encapsulate [99mTc]TcO4−, C-2 was selected for in vivo 
SPECT imaging experiments. MTT assays revealed low cytotoxi-
city relative to administered dose (CC50 = 10.6 μM, see Supporting 
Information).17 [99mTc]TcO4− is used clinically to measure thyroid 
function by replacing iodide in the sodium-iodide symporter (NIS). 
NIS is also expressed in some non-thyroidal tissues including sali-
vary glands, lacrimal glands and stomach.18 When 
[99mTc][TcO4⊂C-2]11+ was administered and imaged, a reproduci-
ble difference in biodistribution was observed, using multiple ani-
mals, separate radiolabelling reactions and also different synthetic 
batches of cage (Figure 5 and S12), with significant uptake noted 
in the liver. These imaging results are consistent with the radio-
chemical stability data, in which a small amount of pertechnetate is 
displaced with blood-based anions, causing some NIS mediated 
thyroid and stomach uptake. Liver uptake vs. renal clearance was 
unexpected and is usually attributed to macrophage uptake of larger 
nano-sized species. In the case of [99mTc][TcO4⊂C-2]11+, the posi-
tive external charge and well defined molecular shape may result 
in protein binding influencing the liver uptake.19 However, liver 
uptake also provides compelling evidence that the capsule remains 
intact during imaging, as disassembly would destroy the high affin-
ity cavity that keeps the anion associated with the cage in the pres-
ence of a vast excess of biological cations. Extraction of liver tissue 
gave a sample with ca. 30% of the [99mTc]TcO4− anion associated 
with the host, with the remainder released (as pertechnetate) during 
the extraction process. The radioactivity associated with the host 
could then be quantitatively released as [99mTc]TcO4− by the addi-
tion of acetonitrile (see Supporting Information). Ex vivo biodistri-
bution studies were carried out post-imaging to quantify uptake in 
various organs at a single time-point (Figure S11). Consistent with 
the SPECT images, the most significant uptake was noted in the 
thyroid (18.77% ID/g), liver (16.52% ID/g) and stomach (38.96% 
ID/g) (full biodistribution graphs are presented in Figure S13). 
  
Figure 5. Comparison of [99mTc]TcO4− uptake in naïve mice (left) 
vs. [99mTc][TcO4⊂C-2]11+ (right). Free [99mTc]TcO4− was injected 
into a naïve anaesthetised animal 40 minutes prior to a 20 minute 
SPECT acquisition. Caged [99mTc]TcO4− was injected into a naïve 
anaesthetised animal 20 minutes prior to a 100 minute SPECT ac-
quisition. Encapsulation results in reduced thyroid and stomach up-
take, and increased liver uptake. Images are maximum intensity 
coronal projections. Additional examples are provided in the Sup-
porting Information. S=Stomach, Th = Thyroid, L=Liver.  
While the (pre)clinical use of self-assembled carrier systems is 
still in its infancy, we have demonstrated a clear step forward, 
showing both the robustness of a CoIII4L6 cage in vivo and that bind-
ing the [99mTc]TcO4− anion significantly affects its biodistribution. 
While this perturbation almost certainly arises due to a difference 
in size and charge, the potential to modify the cage exterior for tar-
geted molecular-delivery is clear, most obviously utilizing the 
amino groups for conjugation with peptides or other biologically 
relevant targeting groups.20 While we are currently optimising this 
radiolabel encapsulation approach, to reduce the amount of “cold” 
precursor required, this method provides a clear benefit both in 
terms of simplicity and speed.  While the decay of [99mTc]TcO4− is 
relatively slow, we anticipate this could be very advantageous for 
some of the shorter lived PET isotopes.21 Consequently, we foresee 
that this or similar systems could act as a universal platform for 
multiple imaging modalities and be expanded to the delivery of ra-
diotherapeutic isotopes including rhenium-188.22   
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